-
Sequential CD20 CAR-T Therapy is Superior to Salvage Chemotherapy in B-cell Lymphoma Patients with CD19 CAR-T Treatment Failure
In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T treatment is ineffective or those who relapse after a brief period of effectiveness. Beyond exploring factors that may affect the efficacy of CD19 CAR-T therapy, many doctors and researchers are actively seeking effective treatments…
-
Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial
In a significant advancement in cancer research, Dr. Zefei Jiang and his team from The Fifth Medical Center of Chinese PLA General Hospital published the article “Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial” in Nature Medicine(IF=83) on January 1, 2024. This pivotal study investigates the efficacy and…
-
New Insights: IP + IV Paclitaxel Plus S-1 Boosts Survival in Gastric Cancer Patients with Peritoneal Metastasis
Noninvasive intraperitoneal chemotherapy (NIPS) has been explored as a promising treatment approach to enhance drug exposure in peritoneal metastasis while reducing systemic toxicity. Previous studies at our center have investigated…
-
Dr. Yongmei Yin：Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial
In a significant advancement in cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article “Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial” in JAMA Oncology on April,…
-
Dr. Zefei Jiang Reviews 2023 Advances in Breast Cancer Research
In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article summarizes Professor Jiang’s speeches and highlights key advances in breast cancer treatment in 2023.
-
ASCO GI | Advancing Targeted Therapy for Gastric Cancer: Insights from Dr. Anna Dorothea Wagner
Oncology Frontier: Could you please introduce the current status of virtual targeted treatment for gastric cancer? Dr. Anna Dorothea Wagner: It’s my pleasure to respond to this question. Currently, adding…
-
Dr. Zefei Jiang ‘s Overview of Breast Cancer Research Progress in 2023
In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang’s speeches, exploring the key advancements in breast cancer treatment in 2023.
Connecting Medical Expertise through Media
